

2.1 Neoadjuvant Treatment Paclitaxel

Patient ID

(Use a short abbreviation of the centre as a prefix and an anonymised numeric patient ID (e.g. MMCI-001).)

Individual Paclitaxel Administrations

Date of the administration of Paclitaxel

Time from diagnosis to the administration of Paclitaxel (derived)

(Number of days between diagnosis and date of this cycle.)

Time from diagnosis to the administration of Paclitaxel

(Number of days between diagnosis and date of this cycle.)

Dose of Paclitaxel in this cycle

(Dose during cycle with values in milligrams per square meter (mg/m²).)

Reduction in dose of Paclitaxel during this cycle

- ☐ No dose reduction
☐ Dose reduction

Dose Reduction of Neoadjuvant Paclitaxel - reasons

- ☐ Neuropathy
☐ Neutropenia
☐ Liver Toxicity
☐ Allergy
☐ Disease Progression
☐ Another Medical Reason
☐ Other Reason (non-medical)
☐ Unknown

Prolongation of the interval since the last Paclitaxel cycle

- ☐ No prolongation
☐ Prolongation

Prolongation of the interval of Neoadjuvant Paclitaxel - reasons

- ☐ Neuropathy
☐ Neutropenia
☐ Liver Toxicity
☐ Allergy
☐ Disease Progression
☐ Another Medical Reason
☐ Other Reason (non-medical)
☐ Unknown

Early Cessation of Paclitaxel
(meaning that this is the last cycle)

- ☐ No early cessation
☐ Early cessation

Early Cessation of Neoadjuvant Paclitaxel - reasons

- ☐ Neuropathy
- ☐ Neutropenia
- ☐ Liver Toxicity
- ☐ Allergy
- ☐ Disease Progression
- ☐ Another Medical Reason
- ☐ Other Reason (non-medical)
- ☐ Unknown